Levosimendan: From coronary care to intensive care?

Intensive Care Medicine

Volumn 37, Issue 4, 2011, Pages 569-571

  Stuart Smith, Karen ^a  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; LEVOSIMENDAN; NITRIC OXIDE;

CORONARY CARE UNIT; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HYPOXIA; INTENSIVE CARE; SEPSIS; VASODILATATION;

ANTI-ARRHYTHMIA AGENTS; CARDIAC OUTPUT; HUMANS; HYDRAZONES; INTENSIVE CARE UNITS; PYRIDAZINES;

EID: 79953821925     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-011-2204-6     Document Type: Editorial

References (18)

1. Follath F (2009) Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Dev Ther 3:73-78
2. Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G (2010) Intravenous levosimendan versus dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 12:404-410
3. 2+ sensitizers. Circ J 72:1915-1925
4. Haikala H, Linden IB (1995) Mechanism of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1):10-19
5. 2 consumption in dogs. Am J Physiol Heart Circ Physiol 294:H238-H248
6. Segreti JA, Marsh KC, Polakowski JS, Fryer RM (2008) Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1, 4, 5, 6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4, 5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J Pharmacol Exp Ther 325:331-340
7. ATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea-pig heart. Br J Pharmacol 154:41-50
8. ATP channel. Br J Pharmacol 156:250-261
9. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, Singer M (2009) Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 102:198-204
10. Pinto BB, Rehberg S, Ertmer C, Westphal M (2008) Role of levosimendan in sepsis and septic shock. Curr Opin Anaesth 21:168-177
11. De Kock I, Van Daele C, Poelaert J (2010) Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy. Acta Clin Belg 65:323-329
12. De Becker D, Bracht H (2009) Levosimendan in early sepsis: when good ideas give poor results. Anesth Analg 109:1367-1369
13. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietropaoli P (2005) Effect of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638-644 (Pubitemid 40684980)
14. Cunha-Goncalves D, Perez-de-Sa V, Grins E, Dahm PL, Thörne J, Blomquist S (2009) Inotropic support during experimental endotoxemic shock: part I. The effects of levosimendan on splanchnic perfusion. Anesth Analg 109:1568-1575
15. Cunha-Goncalves D, Perez-de-Sa V, Larsson A, Thörne J, Blomquist S (2009) Inotropic support during experimental endotoxemic shock: part II. A comparison of levosimendan with dobutamine. Anesth Analg 109:1576-1583
16. Rehberg S, Ertmer C, Vincent JL, Spiegel HU, Köhler G, Erren M, Lange M, Morelli A, Seisel J, Su F, Van Aken H, Traber DL, Westphal M (2010) Effects of combined arginine vasopressin and levosimendan on organ function on ovine septic shock. Crit Care Med 38:2016-2023
17. Schwarte LA, Schwartges I, Thomas K, Schober P, Picker O (2011) The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia. Intensive Care Med. doi: 10.1007/s00134-011-2144-1
18. +-channels. J Pharmacol Sci 104:1-5